Celularity CELU
NASDAQ CELU
$0.80 -0.02 (-2.01%)
As of: Aug 21, 2026 · 3:59 PM EDT

Celularity (CELU) Income towards Parent Company (2019 - 2025)

Celularity (CELU) posted quarterly Income towards Parent Company of -$24.4 million for Q4 2025, down 83.26% year-over-year from -$145.5 million in Q4 2024, and down 5.56% quarter-over-quarter from -$23.1 million in Q3 2025.

Celularity (CELU) Income towards Parent Company (2019 - 2025) Analysis & Trends

Celularity (CELU) has reported Income towards Parent Company for 7 consecutive years, with -$24.4 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Income towards Parent Company fell 83.26% year-over-year to -$24.4 million; the TTM figure through Dec 2025 stood at -$91.7 million (down 58.42% YoY), while the FY2025 annual figure was -$91.7 million, down 58.43% from the prior year.
  • Income towards Parent Company slipped to -$24.4 million in Q4 2025 per CELU's latest filing, from -$23.1 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $49.9 million in Q3 2021 and bottomed at -$93.9 million in Q3 2023.
  • Historically, Income towards Parent Company has averaged -$21.6 million across 5 years, with a median of -$20.9 million in 2024.
  • Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 704.8% — and 2023, when it tumbled 2056.16%.
  • Celularity's Income towards Parent Company stood at -$4.0 million in 2021, then surged by 704.8% to $24.4 million in 2022, then tumbled by 60.93% to $9.5 million in 2023, then plunged by 239.23% to -$13.3 million in 2024, then plunged by 83.26% to -$24.4 million in 2025.
  • Business Quant data shows CELU's Income towards Parent Company at -$24.4 million in Q4 2025, -$23.1 million in Q3 2025, and -$24.5 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Celularity 20.99 Mn 14.82 Mn -3.27 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -24.36 Mn
Sep 30, 2025 -23.08 Mn
Jun 30, 2025 -24.52 Mn
Mar 31, 2025 -19.75 Mn
Dec 31, 2024 -13.29 Mn
Sep 30, 2024 -16.10 Mn
Jun 30, 2024 -6.49 Mn
Mar 31, 2024 -22.01 Mn
Dec 31, 2023 9.55 Mn
Sep 30, 2023 -93.88 Mn
Jun 30, 2023 -47.95 Mn
Mar 31, 2023 -64.02 Mn
Dec 31, 2022 24.43 Mn
Sep 30, 2022 4.80 Mn
Jun 30, 2022 47.83 Mn
Mar 31, 2022 -62.87 Mn
Dec 31, 2021 -4.04 Mn
Sep 30, 2021 49.94 Mn
Jun 30, 2021 -64.52 Mn
Mar 31, 2021 -81.50 Mn